
Whales Are Stacking This Top Altcoin: Kaanch Network Gathers Momentum Ahead of Exchange Listing
Currently in Stage 6 of its presale, Kaanch tokens are priced at just $0.32. The project has already raised over $2.25 million, signaling growing market enthusiasm. Investors are rushing to acquire tokens before the price doubles in the upcoming presale phase to $0.64, and before its anticipated listing on BitMart at a fixed price of $30 per token.
Whales Are Accumulating Ahead of a Potential 200x Surge
The interest of investors in Kaanch is increasing, as the presale has already collected more than 2.25 million dollars. The present price of 0.32 will be doubled to 0.64 in the next presale phase, which will create a sense of urgency among buyers who want to get the best out of it. The next listing of the project on BitMart at a price of 30 is likely to push the demand further. This is due to the high presale energy and a well-placed listing that explains why big investors, also known as whales, are piling on Kaanch tokens in the hope of a substantial rise in value.
Kaanch Outperforms Established Layer 1s with Superior Technology
Technological features of Kaanch make it the most superior Layer 1 blockchain within the market. It can handle 1.4 million transactions per second, and its finality time is only 0.8 seconds, which is far superior to Ethereum and Solana, which still have problems with scalability and high gas fees even after the latest upgrades. Kaanch is perfect to use in decentralized applications, microtransactions, and payments, and its network of 3,600 decentralized nodes is secure and reliable because of near-zero gas fees. This performance edge makes Kaanch scalable and cost-efficient to mass adoption.
Presale Details and Investor Incentives
Kaanch is in Stage 6 of its presale and the tokens are priced at $0.32, with the next stage increasing the price by a factor of two to $0.64. During the presale, investors will have the opportunity to buy tokens with either ETH or USDT and enjoy live staking rewards of up to 30% APY. The limited number of 58 million tokens removes the issue of inflation, which increases scarcity and the possible increase in value. SpyWolf and VerifyLab have audited the project, which provides an extra level of security and transparency, which is attractive to investors with infrastructure focus.
Upcoming BitMart Listing to Catalyze Growth
The listing of Kaanch on Bitmart will take place in the near future, and the fixed price of listing will be 30 dollars per token. This event is a significant catalyst that may cause significant price increases, given that the presale price is much lower. Liquidity and wider market access will be offered by the listing, and it will be a significant step in the development of the project.
Why Investors Should Act Now
Kaanch is not a Layer 1 blockchain like any other, it addresses the scalability problem that has plagued networks such as Solana and the high gas fees that are still plaguing Ethereum even after recent upgrades like the PECTRA update. Its speed, which is unparalleled, low fees, and strong governance structure make it an outstanding infrastructure project. Those investors who want to get involved in such a rapid presale are to visit the official Kaanch presale site and purchase tokens before the prices increase and the BitMart listing becomes available. It is an uncommon chance to be a part of a project that is on the verge of explosive growth and has solid fundamentals and proven traction.
For more information about Kaanch Network ) visit the links below:
Website: https://presale.kaanch.com/
Whitepaper: https://docs.kaanch.network/
Twitter/X: https://x.com/KaanchNetwork
Telegram: https://t.me/kaanchnetwork
Win 1M: https://presale.kaanch.com/win-1-million
How to buy : https://presale.kaanch.com/how-to-buy
FAQs
Q: What is Kaanch Network?
A: Kaanch Network is a high-performance Layer 1 blockchain designed to overcome the scalability and cost limitations of traditional networks like Ethereum and Solana.
Q: How fast is the Kaanch blockchain?
A: Kaanch processes up to 1.4 million transactions per second with a finality time of 0.8 seconds.
Q: What makes Kaanch unique compared to other blockchains?
A: Its speed, near-zero gas fees, robust node infrastructure, and scalability make it highly suitable for dApps, microtransactions, and real-world payments.
Q: How can I participate in the Kaanch presale?
A: You can join the presale using ETH or USDT through the official site: https://presale.kaanch.com .
Q: What is the expected listing price on BitMart?
A: Kaanch is set to list at a price of $30 per token on BitMart.
Q: Are there any rewards for early investors?
A: Yes, early investors can earn up to 30% APY through live staking during the presale phase.
Q: Has the project been audited?
A: Yes, Kaanch has been successfully audited by SpyWolf and VerifyLab, ensuring greater transparency and security for investors.
Q: What is the best crypto to buy now?
A: While market conditions can vary, Kaanch Network stands out due to its unmatched transaction speed, low fees, and strategic positioning ahead of its BitMart listing. With a strong development roadmap, proven audit credentials, and a capped supply of only 58 million tokens, Kaanch offers early investors an opportunity that combines innovation with scarcity-driven value.
Q: What are the top altcoins to buy now?
A: Among top-performing altcoins gaining attention, Kaanch ranks highly due to its infrastructure-first approach, ability to handle 1.4 million TPS, and its application potential across DeFi, payments, and real-world dApps. Investors looking for emerging leaders beyond Bitcoin and Ethereum are watching Kaanch closely.
Q: What are the best cheap cryptos to buy in 2025?
A: Kaanch is currently priced at $0.32 in its presale, making it one of the most undervalued high-potential cryptos. With superior Layer 1 capabilities and a looming $30 exchange listing, its current price point represents a unique buying opportunity.
Q: What is the best cryptocurrency to buy under $1?
A: Kaanch is one of the most compelling options under $1 due to its combination of technological superiority, limited supply, staking rewards, and imminent exchange listing. It provides exposure to a next-gen blockchain infrastructure before it hits mainstream markets.
Disclaimer: This is a paid post and is provided by Kaanch Network. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice.Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed.Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4b3bbb86-914a-471e-8d5e-9762f9b43bff
https://www.globenewswire.com/NewsRoom/AttachmentNg/1ed49965-27c4-4299-8617-d59a5c1dccd7
https://www.globenewswire.com/NewsRoom/AttachmentNg/718a3eb1-13ee-4f27-89c6-05549a8f75d9
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Clinical Trial Biorepository and Archiving Solutions Market Size Expected to Attain USD 9.69 Billion by 2034
The global clinical trial biorepository and archiving solutions market is valued at USD 4.76 billion in 2025 and is projected to reach approximately USD 9.69 billion by 2034, expanding at a CAGR of 8.21% during the forecast period, according to a study published by Towards Healthcare, a sister company of Precedence Research. Ottawa, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global clinical trial biorepository and archiving solutions market was valued at USD 4.4 billion in 2024 and is projected to reach approximately USD 9.69 billion by 2034, expanding at a CAGR of 8.21%. The market is fueled by accelerating research and development in different fields of healthcare. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America was dominant in the clinical trial biorepository and archiving solutions market by 49% shares in 2024. Asia Pacific is expected to grow at the fastest CAGR during 2025-2034. By service, the biorepository services segment led the market in 2024. By service, the archiving solution services segment is expected to grow notably in the upcoming years. By product, the clinical products segment dominated the clinical trial biorepository and archiving solutions market in 2024. By product, the preclinical products segment is expected to grow at a notable CAGR in the studied years. By phase, the preclinical segment registered dominance in the market in 2024. By phase, the phase II segment is expected to grow at a rapid CAGR during 2025-2034. Market Overview & Potential Primarily, the clinical trial biorepository and archiving solutions market comprises the secure storage and management of biological samples (like blood, tissue, and DNA) and linked data from clinical trials. Alongside, it has widespread application in various areas, like clinical research, pharmaceutical development, and personalized medicine, with the increasing focus on data integrity and regulatory compliance. Apart from this, expanding data management, optimizing sample storage, and enhancing the use of digital solutions for compliance and collaboration are propelling the overall adoption and expansion of clinical trial biorepository and archiving solutions. What are the Major Growth Drivers Involved in The Growth of The Market? The clinical trial biorepository and archiving solutions market is driven by continuous groundbreakings in biobanking technologies, like automation and data analytics, which are boosting the effectiveness and accuracy of biorepository operations. Along with this, the widespread application of centralized biorepositories and cloud-based archiving solutions possesses greater accessibility, collaboration, and data management is also impacting the overall market development. You can place an order or ask any questions, please feel free to contact us at sales@ What are the Key Trends Associated with the Market? The clinical trial biorepository and archiving solutions market is developing due to the requirement for efficient sample management, regulatory guidelines for data integrity, and the growing demand for personalized medicine and genomic research. In February 2025, Charles River and Deciphex extended their global partnership to progress digital pathology offering with exclusive image management solutions. In January 2025, Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, and Cryoport, Inc., a global company in supply chain solutions for the life sciences industry, collaborated to offer CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. What is the Arising Challenge in the Market? In the clinical trial biorepository and archiving solutions market, accelerating expenses for the establishment and maintenance of biorepositories are essential. Moreover, this needs wide-range investments in infrastructure technology, such as temperature-controlled storage, as well as participation of specialized personnel are also creating barriers in the market expansion. Eventually, small-scale and emerging organizations may experience these hurdles in their development. Regional Analysis Become a valued research partner with us - How Did North America Dominate the Market in 2024? In 2024, North America held the biggest revenue share of 49% in the clinical trial biorepository and archiving solutions market. This region fosters an advanced pharmaceutical sector, with numerous clinical trials, and a phenomenal network of biobanks and research institutions. Along with this, major investments in the R&D department by leading players in the US and Canada are boosting the comprehensive development. Apart from this, the US FDA's stricter regulatory landscape enables adequate biorepository solutions for sample and data May 2025, Cybin Inc., a clinical-stage advanced neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, announced its participation in the Alliance Global Partners Healthcare Company Showcase. In January 2025, ONCare Alliance and partnered to develop a multi-omics database and biobank to accelerate biomarker discovery in oncology. What to Expect from Asian Countries in Clinical Trial Biorespository and Archiving Solutions Market? Asia Pacific is anticipated to grow at the fastest CAGR in the clinical trial biorepository and archiving solutions market. Several eminent companies of ASAP countries like China, India, and Japan, resulting in a higher demand for specialized biorepository and archiving solutions. Furthermore, they are supporting the development rigorous clinical trials platform globally. Besides this, ongoing advances in biobanking technologies, especially automated sample handling, cryopreservation techniques, and digital archiving, are optimizing the efficiency and reliability of biorepository solutions. For instance, In June 2025, iNGENū CRO entered into a partnership with Quantum BioPharma to launch a pioneering Australian clinical trial for chronic nociplastic pain in MCAS patients. In February 2025, LabConnect and Australian Clinical Labs' (ACL) Specialised Trials forged a strategic collaboration to boost support of clinical trials in Australia and the Asia-Pacific region. Get the latest insights on healthcare industry segmentation with our Annual Membership: Segmental Insights By Service Analysis Why did the Biorepository Services Segment Lead the Market in 2024? The biorepository services segment held a dominating share of the clinical trial biorepository and archiving solutions market in 2024. Primarily, the segment is propelled by the wider demand for biorepository services in oncology research and customized medicine. Along with this, these services are increasingly merged in the safe and secure storage of biological samples, which are vital for biomarker discovery, treatment response analysis, and targeted therapy development. Whereas, various biorepositories are termed as biosample libraries, providing valuable resources for studies focused on enhancing individual patient care and advancing medical knowledge. Although the archiving solution services segment is predicted to expand at a significant CAGR during 2025-2034. This service plays a prominent role in the maintenance of comprehensive patient records and the facilitation of access to historical medical data, which is necessary for precise diagnoses and efficient healthcare delivery. They also manage a large volume of data during clinical trials, comprising lab results, patient records, and imaging data, ensuring data integrity and accessibility. In the security of significant biological samples and data, these services are acting as a major component in the research findings. By Product Analysis How did the Clinical Products Segment Hold the Largest Share of the Market in 2024? In 2024, the clinical products segment led the clinical trial biorepository and archiving solutions market. This segment mainly encompasses diverse products, such as cryogenic vials, tubes, and other containers designed for long-term preservation of biological samples, as well as barcodes, RFID tags, and software to track samples throughout the trial lifecycle. Additionally, specialized containers and equipment for sample handling are important in early-stage research. Also, these kinds of products provide the maintenance of sample viability, prevention of degradation, and allowance for accurate analysis. However, the preclinical products segment will expand significantly during 2025-2034. Across the globe, various ongoing preclinical studies that need strong sample management for toxicology and genetic analysis fuel the demand for advanced biorepository and archiving systems. As well as preclinical biorepositories, it provides controlled environments, including temperature, humidity, etc., to control the integrity of biological samples, such as tissues, cells, and blood, which are major aspects for accurate analysis and validation. Preclinical products usually consist of different technologies and methodologies for processing and preserving samples, maintaining their quality for downstream analysis. This further expands the drug development process. By Phase Analysis How did the Preclinical Segment Dominate the Market in 2024? In the clinical trial biorepository and archiving solutions market, the preclinical segment captured a major revenue share in 2024. The segment is driven by a rise in R&D spending by numerous biopharmaceutical companies, which is resulting in greater preclinical studies and an enhanced need for trustworthy biorepository and archiving solutions. Nowadays, the preclinical studies are widely employed in the growing development of precision medicine, extensive sample analysis. The phase II segment is anticipated to expand rapidly in the coming years. This phase is related to the study of a drug's efficacy, safety, and potential side effects, which requires meticulous archived and connecting with the corresponding biological samples. During this phase, diverse biological samples, like blood, tissue, and other biospecimens, are collected with the application of biorepositories for their storage. Moreover, the segment is impacted by strict regulatory rules for clinical trials, such as those regarding data integrity and sample preservation, which also propel the need for reliable biorepository and archiving solutions. Browse More Insights of Towards Healthcare: The clinical trial investigative site network market was valued at USD 8.36 billion in 2023 and is projected to reach USD 15.99 billion by 2034, expanding at a CAGR of 6.07% from 2024 to 2034. The global cell and gene therapy clinical trials market stood at USD 10.8 billion in 2024, increased to USD 12.47 billion in 2025, and is expected to climb to USD 45.31 billion by 2034, registering a strong CAGR of 15.43% during 2025–2034. The clinical genomics market was valued at USD 1.06 billion in 2024, grew to USD 1.25 billion in 2025, and is anticipated to reach USD 5.34 billion by 2034, expanding at a CAGR of 17.54% between 2025 and 2034. The preclinical advanced cell models market is witnessing strong momentum and is set to generate substantial revenues, with estimates indicating growth into the hundreds of millions by 2034. The AI in clinical trials for drugs market is also on a robust growth path, projected to achieve significant revenue gains, potentially reaching into the hundreds of millions from 2025 to 2034. The clinical data analytics market was valued at USD 81.65 billion in 2024, rose to USD 104.16 billion in 2025, and is forecasted to surge to USD 930.01 billion by 2034, reflecting an impressive CAGR of 27.57% between 2025 and 2034. The clinical trial design market stood at USD 567.66 million in 2024, grew to USD 613.25 million in 2025, and is projected to reach USD 1,228.57 million by 2034, expanding at a CAGR of 8.04% from 2025 to 2034. The preclinical CRO market was valued at USD 6.8 billion in 2025 and is expected to grow to USD 14.34 billion by 2034, advancing at a CAGR of 8.73% during 2025–2034. The core clinical molecular diagnostics market was estimated at USD 5.3 billion in 2023 and is set to reach USD 14.45 billion by 2034, growing at a CAGR of 9.54% between 2024 and 2034. The decentralized clinical trials (DCTs) market stood at USD 8.29 billion in 2023 and is forecasted to rise to USD 38.2 billion by 2034, with a CAGR of 14.9% from 2024 to 2034. Recent Developments In August 2025, Union Minister Dr. Jitendra Singh launched the country's first Animal Stem Cell Biobank at the National Institute of Animal Biotechnology (NIAB), equipped with 3D bioprinting, advanced cryostorage. In May 2025, Sapio Sciences unveiled an innovative Biorepository Management solution, with accelerated sample management capabilities and platform-wide improvements created to simplify lab operations and support high-throughput research environments. In May 2025, Markel Insurance, the insurance operations within Markel Group Inc., launched its Clinical Trials insurance product to provide best-in-class solutions to assist clinical trials research and product development on an international scale. In April 2025, Axtria Inc., an AI-first data analytics innovator transforming life sciences, introduced LUCCID, short for LLM-based Unstructured Clinical Concept Identification, a novel GenAI-powered solution. In January 2025, Stoke Therapeutics announced alignment with global regulatory agencies and plans to initiate a phase 3 study of Zorevunersen as probably the foremost disease-modifying medicine for the treatment of Dravet syndrome. Clinical Trial Biorepository and Archiving Solutions Market Key Players Medpace American Type Culture Collection (ATCC) Cell&Co BioServices (Cryoport) Brooks Life Sciences (Azenta, Inc.) Patheon (Thermo Fisher Scientific, Inc.) Precision Medicine Group, LLC. Labcorp Drug Development Q2 Solutions LabConnect Charles River Laboratories Segments Covered in The Report By Service Biorepository Services Warehousing & storage Transportation Sample Processing Others Archiving Solution Services Database Indexing and Management Scanning & Destruction By Product Preclinical Products Clinical Products Human Tissue Organs Stem cells Other Biospecimens By Phase Preclinical Phase I Phase II Phase III Phase IV By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait To invest in our premium strategic solution and customized market report options, click here: You can place an order or ask any questions, please feel free to contact us at sales@ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
an hour ago
- Business Insider
Ethereum Meme Coin Pepeto Crosses $6,200,000 Million in Presale Upon Listing
Early-stage crypto presales offer access to tokens at initial valuations prior to public market listings. On August 15, Ethereum reached $4,750, reflecting upward momentum amid shifting altcoin market indicators. As of August 19, ETH remains above $4,300 following a recent correction, positioning it near previous high levels. Ethereum-based token Pepeto ($PEPETO) has surpassed $6 million in contributions during its presale. Priced at $0.000000147 per token, Pepeto has attracted attention within the cryptocurrency sector. The project differentiates itself through a zero-fee exchange and PepetoSwap technology, supported by a cross-chain bridge and a staking mechanism currently offering 242% rewards. This combination of utility features and meme token branding positions it within a competitive market landscape. Each presale stage has closed in a relatively short timeframe, consistent with patterns seen in previous meme token initiatives, while indicating ongoing development efforts and community involvement. Pepeto is developed on the Ethereum network, incorporating meme-themed branding alongside technical components. Its zero-fee exchange is intended to address transaction costs, a common barrier for traders. In addition, PepetoSwap and an integrated cross-chain bridge aim to facilitate trading across multiple blockchains, potentially increasing accessibility across various user groups. With a focus on affordability, transaction efficiency, and interoperability, Pepeto is structured to appeal to a broad range of users as it moves from the presale phase toward its planned launch. Technical Value and Audits Add a Layer of Trust Pepeto's development has undergone independent audits, complementing its core utilities that distinguish it from conventional meme tokens. The integration of security measures with technical infrastructure contributes to the foundation of its long-term functionality: • Pepeto Exchange: a zero-fee trading platform designed to host and list the next wave of meme coins and Web3 projects • PepetoSwap Technology: enabling seamless token swapping across chains with fast execution • Cross-Chain Bridge: connecting multiple blockchains, improving interoperability and accessibility • Staking Rewards: offering 242% APY to incentivize long-term holding and ecosystem growth • SolidProof Audit: comprehensive code review by a respected blockchain security firm • Coinsult Audit: an additional audit ensuring transparency and security for cautious investors Community Engagement and Expanding Presence Community involvement has played a key role in Pepeto's visibility to date. The project has maintained active outreach through social media channels, AMAs, and interactive campaigns, accumulating over 100,000 combined followers. This activity has supported consistent visibility within a competitive market environment. Rather than relying on short-term promotions, Pepeto's outreach approach emphasizes ongoing engagement, aiming to build user trust and support gradual awareness within the broader cryptocurrency landscape. Global Participation and Presale Structure Pepeto's presale has been open to participants globally, supported by a low entry price and a simplified purchase process. This approach has aimed to reduce access barriers for new users, while allowing others to engage during the presale phase. The presale operates on a tiered pricing model, with token prices increasing at each stage. Currently in Stage 8 and approaching Stage 9, the presale structure reflects patterns observed in earlier meme token launches. Embedded Youtube link : Positioning Within the Meme Token Landscape With over $6 million raised, dual audit verification, and features including a zero-fee exchange, PepetoSwap, and a staking mechanism currently offering 242% rewards, Pepeto presents a broader utility framework compared to typical meme tokens. Its reference to the original Pepe narrative—sharing the same 420 trillion supply while reinterpreting it as PEPE + TO—adds a thematic dimension to its branding. As the project progresses toward token launch and prepares its exchange for listing future meme tokens and Web3 projects, it continues to build out its infrastructure. This development focus may support broader engagement beyond initial market entry. How to Buy $PEPETO Investors can join the $PEPETO presale via the official website: Tokens are available at $0.000000147, with payment options including USDT, ETH, and BNB. Early participants can capitalize on staking rewards up to 242% and other exclusive ecosystem benefits. About $PEPETO $PEPETO is a cutting-edge cryptocurrency project blending the playful spirit of meme coins with real-world utility. Featuring a zero-fee exchange, cross-chain bridge, and unparalleled staking rewards, $PEPETO is redefining what it means to be a meme coin in 2025. Disclaimer: To buy PEPETO, make sure to use the official website: As the listing draws closer, some are attempting to capitalize on the hype by using the name to mislead investors with fake platforms. Stay cautious and verify the source. Website: Contact Author DANIEL B


Business Insider
2 hours ago
- Business Insider
The Real-Time ETH Trade Tracker That Crushed Wall Street
InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the biggest challenges in trading is keeping track of all the pieces at once. Prices bounce around. News breaks. Market correlations change on a dime. And if you can't see how everything connects in real time, you're always one step behind. It's a lot like watching a football game on TV. You see the camera cut to the quarterback, maybe a flash of the receiver, then the ball's in the air. But you don't see what's happening across the rest of the field — the safety creeping up, the cornerback cheating inside, the linebacker dropping back into coverage. All the things that tell you where the play is going before it happens are hidden from view. Now, when you're at the stadium, it's a different story. You can see the whole field — all 22 players. You watch the defense shift. You see the gap open before the snap. You know, before the quarterback even throws, exactly where the ball should go. That wide view changes everything. That's the kind of perspective I realized we needed to understand the explosion around Ethereum. For weeks, I'd been talking about how certain companies hold huge amounts of ETH in their treasury — and how their stock prices don't always match the value of what they own. Those mismatches are opportunities, but they open and close fast. One day, while I was breaking this down live for our members — digging through filings, lining up ETH prices, stock prices, market caps — it hit me: we were watching the game on TV. We were piecing together the action from different angles, different screens, different charts… but we couldn't see the whole field at once. So I built a tool that does exactly that. One screen. All the companies, all their ETH holdings, their market caps, and whether they're trading at a premium or a discount — updating in real time. Now, when Wall Street's defense blows an assignment, we see it instantly. And when we see the opening, we can move before the rest of the market even knows it's there. This tool is our ticket to the stadium — the full-field view that lets us trade like we're on the sidelines, not stuck at home watching the highlights. And in today's Masters in Trading LIVE at 11 AM EST, I want to break down exactly how we used that tool to get a beat on one of the biggest market trends of the year. And I want to explain the tale of one trade we discovered that single-handedly gave us one our biggest-ever crypto based plays. You can watch the video at the end of this post. And I want to make something else very clear. From that ETH trade that was on no one's radar… Masters in Trading has consistently delivered unique setups with massive upside potential. Want to learn the fundamentals behind these big trades? I'm inviting you to take this journey with me. It's all in the special options-trading intensive I designed to take anyone from novice to pro in just seven days. Just click here to learn more. Remember, the creative trader wins, Jonathan Rose Founder, Masters in Trading